1. Home
  2. CSTL vs NX Comparison

CSTL vs NX Comparison

Compare CSTL & NX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$18.95

Market Cap

806.3M

Sector

Health Care

ML Signal

HOLD

Logo Quanex Building Products Corporation

NX

Quanex Building Products Corporation

HOLD

Current Price

$20.17

Market Cap

852.1M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSTL
NX
Founded
2007
1927
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
806.3M
852.1M
IPO Year
2019
2008

Fundamental Metrics

Financial Performance
Metric
CSTL
NX
Price
$18.95
$20.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
1
Target Price
$45.50
$28.00
AVG Volume (30 Days)
269.9K
290.9K
Earning Date
05-06-2026
06-04-2026
Dividend Yield
N/A
1.64%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$344,229,000.00
$1,837,641,000.00
Revenue This Year
$2.42
$4.26
Revenue Next Year
$12.69
$1.77
P/E Ratio
N/A
N/A
Revenue Growth
3.66
43.81
52 Week Low
$14.59
$11.04
52 Week High
$44.28
$22.90

Technical Indicators

Market Signals
Indicator
CSTL
NX
Relative Strength Index (RSI) 25.76 54.49
Support Level $14.59 $18.92
Resistance Level $25.06 $22.64
Average True Range (ATR) 1.27 0.77
MACD -0.22 -0.08
Stochastic Oscillator 2.71 56.33

Price Performance

Historical Comparison
CSTL
NX

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

About NX Quanex Building Products Corporation

Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.

Share on Social Networks: